Sanofi Consumer Healthcare Shares Fell ~2% After Release of Q3FY25 Earnings

On February 21, 2025, Sanofi Consumer share price dropped ~2%, reaching a day low of ₹4,595.15, against the previous close of ₹4,765.65 on BSE. The fall in Sanofi Consumer share price came after the release of Q3FY25 results, wherein it reported a fall in revenue and PAT.

Sanofi Consumer Q3FY25 Earnings Highlights

Sanofi Consumer Healthcare had a tough quarter, as its Q4 financial results revealed a notable decline in earnings. The company experienced a 34.8% decrease in net profit for the December quarter, reporting ₹44.3 crore compared to ₹67.9 crore in the same period last year. Revenue also dropped by 24%, falling to ₹170.7 crore from ₹224.6 crore year-over-year. EBITDA saw a decline of 30.6%, reaching ₹61.1 crore in Q4, down from ₹89.5 crore in the previous year. Consequently, the company’s EBITDA margin shrank to 36.4%, from 39.9% YoY.

These figures reflect a difficult quarter for Sanofi Consumer Healthcare, even with the company’s strong multinational presence in the vaccines and medicines markets across various conditions. The consumer healthcare division emphasizes consumer-focused strategies and digital and e-commerce capabilities. For FY2022, the annual turnover of the consumer healthcare business was ₹730 crore.

Sanofi Consumer Declared Dividend of ₹55

Sanofi Consumer Healthcare India Ltd has declared a final dividend of ₹55 per equity share, each with a face value of ₹10, for the financial year ending December 31, 2024. The company has not yet specified the record date for the dividend payment.

About Sanofi Consumer Healthcare Limited

Sanofi Consumer Healthcare operates in more than 100 countries and offers healthcare solutions across over 170 countries worldwide. With four global business units focusing on key healthcare sectors, the company further strengthens its position in the healthcare industry.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.